Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: A systematic review and meta-analysis

Journal of Hypertension

Volumn 30, Issue 1, 2012, Pages 3-16

  Marchesi, Chiara ^a   Dentali, Francesco ^a   Nicolini, Eleonora ^a   Maresca, Andrea M ^a   Tayebjee, Mazahir H ^b,e   Franz, Marcus ^c   Guasti, Luigina ^a   Venco, Achille ^a   Schiffrin, Ernesto L ^d   Lip, Gregory Y H ^e   Grandi, Anna M ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

blood pressure; heart failure; left ventricular hypertrophy; matrix metalloproteinases; remodeling; tissue inhibitors of matrix metalloproteinases

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

DIASTOLIC HEART FAILURE; EMBASE; ENZYME BLOOD LEVEL; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICULE REMODELING; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 83455245483     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834d249a     Document Type: Review

References (59)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562. (Pubitemid 26154241)
2. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117:568-575. (Pubitemid 46348511)
3. Diez J, Gonzalez A, Lopez B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005; 2:209-216. (Pubitemid 40812484)
4. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75:346-359. (Pubitemid 350298459)
5. Levick SP, Brower GL. Regulation of matrix metalloproteinases is at the heart of myocardial remodeling. Am J Physiol Heart Circ Physiol 2008; 295:H1375-H1376.
6. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40:1362-1378.
7. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C. Clark LTcTissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151:1101-1108.
8. Jefferis BJ, Whincup P, Welsh P, Wannamethee G, Rumley A, Lennon L, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010; 208:557-563.
9. Velagaleti RS, Gona P, Sundstrom J, Larson MG, Siwik D, Colucci WS, et al. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 2010; 30:2283-2288.
10. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010; 29:194-201.
11. Gonzalez A, Lopez B, Ravassa S, Beaumont J, Arias T, Hermida N, et al. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res 2009; 81:509-518.
12. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006; 47:711-717. (Pubitemid 43740243)
13. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005; 166:15-25. (Pubitemid 40051656)
14. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, et al. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 2005; 97:380-390. (Pubitemid 41216143)
15. Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens 2008; 26:322-333.
16. Panek AN, Bader M. Matrix reloaded: the matrix metalloproteinase paradox. Hypertension 2006; 47:640-641. (Pubitemid 43740229)
17. Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53:1119-1129.
18. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 2004; 171:1369-1373. (Pubitemid 39573841)
19. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GYH. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004; 17:770-774. (Pubitemid 39201091)
20. Wallace SY, McEniery C, Dakham Z, Pusalkar P, Maki-Petaja K, Ashby M, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25:372-378. (Pubitemid 40189160)
21. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98:535-540. (Pubitemid 28371251)
22. Saglam M, Karakaya O, Esen AM, Barutcu I, Dogan S, Karavelioglu Y, et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med 2006; 208:117-122. (Pubitemid 43174163)
23. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GYH. Matrix metalloproteinases-9 and tissue inhibitor metalloproteinases-1 levels in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int J Cardiol 2000; 75:43-47.
24. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
25. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9. in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17:119-124. (Pubitemid 36292367)
26. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, et al. Matrix metalloproteinase-2, 9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13:227-231. (Pubitemid 44110588)
27. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure. evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115:888-895. (Pubitemid 46294729)
28. Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, Tsioufis K, et al. The effect of Ca2\+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and 9 in essential hypertension. Am J Hypertens 2004; 17:273-276. (Pubitemid 38293334)
29. Onal KI, Altun B, Onal ED, Krkpantur A, Oz SG, Turgan C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Int Med 2009; 20:369-372.
30. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48:89-96. (Pubitemid 43929208)
31. Stakos DA, Tziakas DN, Chalikias GK, Mitrousi K, Tsigalou C, Boudoulas H. Associations between collagen synthesis and degradation and aortic function in arterial hypertension. Am J Hypertens 2010; 23:488-494.
32. McNulty M, Mahmud A, Spiers P, Feely J, McNulty M, Mahmud A, et al. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens 2006; 20:867-873. (Pubitemid 44614069)
33. Tayebjee MH, Nadar S, Blann AD, Gareth BD, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17:764-769. (Pubitemid 39201090)
34. Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007; 30:959-963. (Pubitemid 350120974)
35. Friese RS, Rao F, Khandrika S, Thomas B, Ziegler MG, Schmid-Schonbein GW, O'Connor DT. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens N Y 2009; 31:521-533.
36. Hirono O, Fatema K, Nitobe J, Takeishi Y, Kaneko K, Shiga R, Kubota I. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension. J Cardiol 2002; 39:195-204. (Pubitemid 40756057)
37. Szmigielski C, Raczkowska M, Styczynski G, Pruszczyk P, Gaciong Z. Metabolism of collagen is altered in hypertensives with increased intima media thickness. Blood Press 2006; 15:157-163. (Pubitemid 44644467)
38. Gonzalez A, Lopez B, Querejeta R, Zubillaga E, Echeverria T, Diez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010; 55:1418-1424.
39. Franz M, Berndt A, Tendorf-Hofmann A, Fiedler N, Richter P, Schumm J, et al. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009; 11:1057-1062.
40. Zile MR, DeSantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011; 4:246-256.
41. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011. [Epub ahead of print].
42. Alloni M, Castaldi G, Corradi B, Cesana F, Cirò A, Vincenti A, et al. Heart failure with preserved ejection fraction (HFPEF): aortic stiffness, biohumoral markers and echocardiographic evaluation. ESH 2011: 4C.04.
43. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertens 2002; 40:136-141. (Pubitemid 34840088)
44. Tayebjee MH, Lim HS, Nadar S, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinse-1 is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertension. Eur J Clin Inves 2005; 35:8-12. (Pubitemid 40187948)
45. Kang SJ, Lim C, Choi B, Choi IS, Hwang GS, Yoon MH, et al. Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension. J Am Soc Echocardiogr 2008; 21:907-911.
46. Timms McLean P, Wright A, Maxwell P, Campbell S, Dawnay AB, Srikanthan V. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002; 15:269-272. (Pubitemid 34226194)
47. Rossignol P, Laurent S, Cambillau M, Mouradian D, Bozec E, Gaussem P, et al. Plasma TIMP/MMP ratios as new circulating biomarkers of the carotid hypertrophy in hypertensive patients. ESH 2008: OS5/2.
48. Cesana F, Castaldi G, Corradi B, Alloni M, Galbiati M, Stucchi M, et al. Antihypertensive drug treatment does not allow to achieve a full normalization of the arterial stiffness and metalloproteinases alterations seen in hypertension. ESH 2011: 5C.03.
49. Ló pez D, Gonzá lez A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 121:1645-1654.
50. Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 2007; 13:530-540. (Pubitemid 47371209)
51. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560. (Pubitemid 37088507)
52. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
53. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477:267-283. (Pubitemid 30119906)
54. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002; 8:390-398. (Pubitemid 36055741)
55. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010; 48:445-453.
56. Dhingra R, Pencina MJ, Schrader P, Wang TJ, Levy D, Pencina K, et al. Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation 2009; 119:1101-1107.
57. Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 2005; 46:598-606. (Pubitemid 41376842)
58. Deschamps AM, Apple KA, Leonardi AH, McLean JE, Yarbrough WM, Stroud RE, et al. Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. Circ Res 2005; 96:1110-1118. (Pubitemid 40796132)
59. Wang Y, it-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest 2010; 120:422-432.